Heart Rate Variability Change After Liver Transplantation

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

National Taiwan University Hospital

ClinicalTrials.gov Identifier:

NCT00778687

First received: October 22, 2008

Last updated: December 22, 2013

Last verified: December 2013

History of Changes

Purpose

Cirrhotic cardiomyopathy describes a hyperdynamic state with the presentation of high cardiac output and low systemic vascular resistance. And the latent heart failure becomes obvious under physiologic and pharmacologic stress. The goal of our study is to assess the effects of liver transplantation on the heart rate variability in patients with end stage liver disease.

Condition
Liver Transplantation


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Effects of Liver Transplantation on the Heart Rate Variability in Patients With End-Stage Liver Disease

Resource links provided by NLM:

MedlinePlus related topics: Liver Diseases Liver Transplantation

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:

Multiscale entropy [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Multiscale entropy was measured at nine time points: 1. preoperative, 2. postoperative day 1, 3. postoperative day 2, 4. postoperative day 3, 5. postoperative day 4, 6. postoperative day 7, 7. postoperative day 14, 8. postoperative 3 months, 9. postoperative 6 months


Enrollment:	30
Study Start Date:	October 2008
Study Completion Date:	January 2010
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients with end stage liver disease undergoing liver transplantation

Criteria

Inclusion Criteria:

Age:18-70y/o receiving liver transplantation

Exclusion Criteria:

History of cardiovascular disease

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00778687

Locations


Taiwan
National Taiwan University Hospital
Taipei, Taiwan

Sponsors and Collaborators

National Taiwan University Hospital

More Information

Publications:

Genovesi S, Prata Pizzala DM, Pozzi M, Ratti L, Milanese M, Pieruzzi F, Vincenti A, Stella A, Mancia G, Stramba-Badiale M. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond). 2009 May 14;116(12):851-9. doi: 10.1042/CS20080325.


Responsible Party:	National Taiwan University Hospital
ClinicalTrials.gov Identifier:	NCT00778687 History of Changes
Other Study ID Numbers:	200809046R
Study First Received:	October 22, 2008
Last Updated:	December 22, 2013
Health Authority:	Taiwan: Department of Health

Additional relevant MeSH terms:


End Stage Liver Disease Liver Failure Hepatic Insufficiency Liver Diseases Digestive System Diseases

ClinicalTrials.gov processed this record on September 23, 2016

To Top